Sharekhan has given Buy recommendation for Cipla with a target price of Rs. 950 in its research report issued on Jan 29, 2021

Sharekhan’s research report on Cipla

Q3FY2021 was a strong quarter with margins expanding sturdily on account of cost optimisation efforts. Results are ahead of estimates. Cipla’s One-India strategy has played out well and has yielded synergies across its business. Increased prescription generation backed by sustained traction in chronic and a likely revival in the acute therapy would drive growth of the India business. Healthy growth prospects across geographies, strong earnings visibility, and a healthy balance sheet augur well and will be key positives for Cipla.


We maintain our Buy recommendation on the stock of Cipla with an unchanged PT of Rs. 950.

For all recommendations report, click here